385 results on '"Resectable Pancreatic Cancer"'
Search Results
2. A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
- Author
-
NovoCure GmbH, Ohio State University, and Ashish Manne, Sponsor-Investigator
- Published
- 2024
3. Intraoperative Radiation Therapy for Resectable Pancreatic Cancer
- Author
-
Yona Cho, Assistant Professor
- Published
- 2024
4. A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer
- Published
- 2024
5. Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes.
- Author
-
Manne, Ashish, Esnakula, Ashwini, Sheel, Ankur, Sara, Amir, Manne, Upender, Paluri, Ravi Kumar, He, Kai, Yang, Wancai, Sohal, Davendra, Kasi, Anup, Noonan, Anne M., Mittra, Arjun, Hays, John, Roychowdhury, Sameek, Malalur, Pannaga, Rahman, Shafia, Jin, Ning, Cloyd, Jordan M., Tsai, Susan, and Ejaz, Aslam
- Subjects
- *
PANCREATIC duct , *NEOADJUVANT chemotherapy , *OVERALL survival , *PROGRESSION-free survival , *PANCREATIC cancer - Abstract
Neoadjuvant therapy (NAT) for early-stage pancreatic ductal adenocarcinoma (PDA) has recently gained prominence. We investigated the clinical significance of mucin 5 AC (MUC5AC), which exists in two major glycoforms, a less-glycosylated immature isoform (IM) and a heavily glycosylated mature isoform (MM), as a biomarker in resected PDA. Immunohistochemistry was performed on 100 resected PDAs to evaluate the expression of the IM and MM of MUC5AC using their respective monoclonal antibodies, CLH2 (NBP2-44455) and 45M1 (ab3649). MUC5AC localization (cytoplasmic, apical, and extra-cellular (EC)) was determined, and the H-scores were calculated. Univariate and multivariate (MVA) Cox regression models were used to estimate progression-free survival (PFS) and overall survival (OS). Of 100 resected PDA patients, 43 received NAT, and 57 were treatment-naïve with upfront surgery (UpS). In the study population (n = 100), IM expression (H-scores for objective response vs. no response vs. UpS = 104 vs. 152 vs. 163, p = 0.01) and MM-MUC5AC detection rates (56% vs. 63% vs. 82%, p = 0.02) were significantly different. In the NAT group, MM-MUC5AC-negative patients had significantly better PFS according to the MVA (Hazard Ratio: 0.2, 95% CI: 0.059–0.766, p = 0.01). Similar results were noted in a FOLFIRINOX sub-group (n = 36). We established an association of MUC5AC expression with treatment response and outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Safety and Feasibility of Neoadjuvant-Modified FOLFIRINOX in Elderly Patients with Pancreatic Cancer.
- Author
-
Shindo, Yoshitaro, Ioka, Tatsuya, Tokumitsu, Yukio, Matsui, Hiroto, Nakajima, Masao, Kimura, Yuta, Watanabe, Yusaku, Tomochika, Shinobu, Nakagami, Yuki, Tsunedomi, Ryouichi, Iida, Michihisa, Takahashi, Hidenori, and Nagano, Hiroaki
- Subjects
- *
PATIENT safety , *PILOT projects , *ASPARTATE aminotransferase , *TREATMENT effectiveness , *RETROSPECTIVE studies , *PANCREATIC tumors , *COMBINED modality therapy , *ALANINE aminotransferase , *NAUSEA , *OLD age - Abstract
Simple Summary: Neoadjuvant chemotherapy (NAC) is effective in improving the prognosis of patients with resectable and borderline resectable pancreatic cancer (PC). A modified FOLFIRINOX (mFOLFIRINOX) regimen is widely used as the standard therapy. However, owing to its toxicity, it is not applied in patients older than 75 years. Furthermore, elderly patients often have concomitant conditions and are at high risk for adverse effects associated with chemotherapy. Given the rapid increase in the number of elderly patients, it is necessary to determine whether NAC can be performed in both non-elderly and elderly patients. Thus, in this study, we investigated the safety and feasibility of neoadjuvant mFOLFIRINOX in elderly patients with PC. We found that the perioperative and postoperative outcomes of elderly patients who received neoadjuvant mFOLFIRINOX were comparable to those of non-elderly patients. The optimal treatment strategy for neoadjuvant chemotherapy in elderly patients with pancreatic cancer (PC) remains unclear. Hence, this study was aimed at evaluating the safety and feasibility of neoadjuvant-modified FOLFIRINOX (mFOLFIRINOX) in elderly patients with PC. We retrospectively collected data from 62 patients who received neoadjuvant mFOLFIRINOX between May 2015 and October 2023 and comparatively analyzed the clinicopathological data and outcomes between the non-elderly group (age: <75 years) and elderly group (age: >75 years). The non-elderly and elderly groups comprised 39 and 23 patients, respectively. Although elevated levels of aspartate aminotransferase (p = 0.0173) and alanine aminotransferase (p = 0.0378) and nausea (p = 0.0177) were more frequent in the elderly group, the incidence of severe adverse events was similar between the groups. Intergroup differences in resection rate (p = 0.3381), postoperative severe complication rates (p = 0.2450), and postoperative hospital stay (p = 0.3496) were not significant. Furthermore, no significant intergroup differences were found in survival in either the whole or the resection cohorts. The perioperative and postoperative outcomes of elderly patients treated with neoadjuvant mFOLFIRINOX were comparable with those of non-elderly patients. Neoadjuvant mFOLFIRINOX should be considered a feasible option for elderly patients with PC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab (CAPT-02)
- Author
-
TingBo Liang, The chairman of the First Affiliated Hospital of Zhejiang University School of Medicine
- Published
- 2023
8. GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma (NeoPancOne)
- Author
-
Pancreatic Cancer Canada
- Published
- 2023
9. A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
- Author
-
Novartis and Kimberly Perez, MD, Principal Investigator
- Published
- 2023
10. Radiochemotherapy in Pancreatic Cancer
- Author
-
Małgorzata Domagała-Haduch, Anita Gorzelak-Magiera, Łukasz Michalecki, and Iwona Gisterek-Grocholska
- Subjects
radiochemotherapy ,unresectable pancreatic cancer ,resectable pancreatic cancer ,borderline resectable pancreatic cancer ,chemotherapy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Despite the advancements made in oncology in recent years, the treatment of pancreatic cancer remains a challenge. Five-year survival rates for this cancer do not exceed 10%. Among the reasons contributing to poor treatment outcomes are the oligosymptomatic course of the tumor, diagnostic difficulties due to the anatomical location of the organ, and the unique biological features of pancreatic cancer. The mainstay of treatment for resectable cancer is surgery and adjuvant chemotherapy. For unresectable and metastatic cancers, chemotherapy remains the primary method of treatment. At the same time, for about thirty years, there have been attempts to improve treatment outcomes by using radiotherapy combined with systemic treatment. Unlike chemotherapy, radiotherapy has no established place in the treatment of pancreatic cancer. This paper addresses the topic of radiotherapy in pancreatic cancer as a valuable method that can improve treatment outcomes alongside chemotherapy.
- Published
- 2024
- Full Text
- View/download PDF
11. Radiochemotherapy in Pancreatic Cancer.
- Author
-
Domagała-Haduch, Małgorzata, Gorzelak-Magiera, Anita, Michalecki, Łukasz, and Gisterek-Grocholska, Iwona
- Subjects
- *
PANCREATIC cancer , *CHEMORADIOTHERAPY , *ADJUVANT chemotherapy , *TREATMENT effectiveness , *ONCOLOGIC surgery , *PANCREATIC tumors , *RADIOTHERAPY - Abstract
Despite the advancements made in oncology in recent years, the treatment of pancreatic cancer remains a challenge. Five-year survival rates for this cancer do not exceed 10%. Among the reasons contributing to poor treatment outcomes are the oligosymptomatic course of the tumor, diagnostic difficulties due to the anatomical location of the organ, and the unique biological features of pancreatic cancer. The mainstay of treatment for resectable cancer is surgery and adjuvant chemotherapy. For unresectable and metastatic cancers, chemotherapy remains the primary method of treatment. At the same time, for about thirty years, there have been attempts to improve treatment outcomes by using radiotherapy combined with systemic treatment. Unlike chemotherapy, radiotherapy has no established place in the treatment of pancreatic cancer. This paper addresses the topic of radiotherapy in pancreatic cancer as a valuable method that can improve treatment outcomes alongside chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial.
- Author
-
Goetze, Thorsten O., Reichart, Alexander, Bankstahl, Ulli S., Pauligk, Claudia, Loose, Maria, Kraus, Thomas W., Elshafei, Moustafa, Bechstein, Wolf O., Trojan, Jörg, Behrend, Matthias, Homann, Nils, Venerito, Marino, Bohle, Wolfram, Varvenne, Michael, Bolling, Claus, Behringer, Dirk M., Kratz-Albers, Karsten, Siegler, Gabriele M., Hozaeel, Wael, and Al-Batran, Salah-Eddin
- Abstract
Background: Although addition of adjuvant chemotherapy is the current standard, the prognosis of pancreatic cancers still remains poor. The NEPAFOX trial evaluated perioperative treatment with FOLFIRINOX in resectable pancreatic cancer. Patients and Methods: This multicenter phase II trial randomized patients with resectable or borderline resectable pancreatic cancer without metastases into arm (A,) upfront surgery plus adjuvant gemcitabine, or arm (B,) perioperative FOLFIRINOX. The primary endpoint was overall survival (OS). Results: Owing to poor accrual, recruitment was prematurely stopped after randomization of 40 of the planned 126 patients (A: 21, B: 19). Overall, approximately three-quarters were classified as primarily resectable (A: 16, B: 15), and the remaining patients were classified as borderline resectable (A: 5, B: 4). Of the 12 evaluable patients, 3 achieved partial response under neoadjuvant FOLFIRINOX. Of the 21 patients in arm A and 19 patients in arm B, 17 and 7 underwent curative surgery, and R0-resection was achieved in 77% and 71%, respectively. Perioperative morbidity occurred in 72% in arm A and 46% in arm B, whereas non-surgical toxicity was comparable in both arms. Median RFS/PFS was almost doubled in arm B (14.1 months) compared with arm A (8.4 months) in the population with surgical resection, whereas median OS was comparable between both arms. Conclusions: Although the analysis was only descriptive owing to small patient numbers, no safety issues regarding surgical complications were observed in the perioperative FOLFIRINOX arm. Thus, considering the small number of patients, perioperative treatment approach appears feasible and potentially effective in well-selected cohorts of patients. In pancreatic cancer, patient selection before initiation of neoadjuvant therapy appears to be critical. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. A resected case of pancreatic head cancer developing 40 years after lateral pancreaticojejunostomy for chronic pancreatitis.
- Author
-
Matsumoto, Takatsugu, Tanaka, Genki, Mori, Shozo, Niki, Maiko, Sato, Shun, Shiraki, Takayuki, Iso, Yukihiro, Nagashima, Kazunori, Irisawa, Atsushi, Nozawa, Yumi, Takada-Owada, Atsuko, Ishida, Kazuyuki, and Aoki, Taku
- Abstract
A 72-year-old male patient presented to our department complaining of with upper abdominal pain and jaundice. He had a history of a side-to-side pancreaticojejunostomy performed 40 years previously for chronic pancreatitis. A diagnostic workup revealed a tumor 3 cm in size in the pancreatic head as the etiology of the jaundice. Subsequently, the patient was diagnosed with resectable pancreatic cancer. Following two cycles of neoadjuvant chemotherapy, an extended pancreatoduodenectomy was performed because of tumor invasion at the previous pancreaticojejunostomy site. Concurrent portal vein resection and reconstruction were performed. Pathological examination confirmed invasive ductal carcinoma (T2N1M0, Stage IIB). This case highlights the clinical challenges in pancreatic head carcinoma following a side-to-side pancreaticojejunostomy. Although pancreaticojejunostomy is believed to reduce the risk of pancreatic cancer in patients with chronic pancreatitis, clinicians should be aware that, even after this surgery, there is still a chance of developing pancreatic cancer during long-term follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)
- Author
-
Seoul St. Mary's Hospital, Seoul National University Bundang Hospital, SMG-SNU Boramae Medical Center, Gangnam Severance Hospital, and Jin-Young Jang, Professor
- Published
- 2023
15. Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer
- Author
-
Susan Tsai, Professor
- Published
- 2023
16. Research and guidelines interpretation of neoadjuvant therapy for resectable pancreatic cancer, promising or limited?
- Author
-
ZHANG Taiping, WENG Guihu, LIU Yueze
- Subjects
resectable pancreatic cancer ,neoadjuvant therapy ,progress and controversies ,standardized treatment ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 ,Surgery ,RD1-811 - Abstract
As a systemic disease, pancreatic cancer is highly malignant and has a high rate of recurrence and metastasis, which makes it particularly difficult in diagnosis, treatment and management. In recent years, with the concept of neoadjuvant therapy deeply rooted in the hearts of the people, the treatment of pancreatic cancer has increasingly emphasized the development of comprehensive and individualized treatment schemes in the whole process and multi-dimensional management of pancreatic cancer patients. However, there still remain many controversies about the application of neoadjuvant therapy for resectable pancreatic cancer. This review intended to discuss the hot topics and related controversies in the implementation of neoadjuvant therapy for patients with resectable pancreatic cancer based on domestic and foreign guidelines and the latest research progress, which may vastly promote the standardized application of neoadjuvant therapy for resectable pancreatic cancer.
- Published
- 2024
- Full Text
- View/download PDF
17. Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
- Published
- 2023
18. Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer (NEONAX)
- Author
-
Celgene and ClinAssess GmbH
- Published
- 2023
19. Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
- Published
- 2023
20. Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer (CIRCPAC)
- Author
-
Aarhus University Hospital, University of Copenhagen, Odense University Hospital, and Prof. Julia Sidenius Johansen, Professor
- Published
- 2023
21. Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer
- Published
- 2023
22. Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer (ICAPAC)
- Published
- 2023
23. Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes
- Author
-
Ashish Manne, Ashwini Esnakula, Ankur Sheel, Amir Sara, Upender Manne, Ravi Kumar Paluri, Kai He, Wancai Yang, Davendra Sohal, Anup Kasi, Anne M. Noonan, Arjun Mittra, John Hays, Sameek Roychowdhury, Pannaga Malalur, Shafia Rahman, Ning Jin, Jordan M. Cloyd, Susan Tsai, Aslam Ejaz, Kenneth Pitter, Eric Miller, Kannan Thanikachalam, Mary Dillhoff, and Lianbo Yu
- Subjects
pancreatic adenocarcinoma ,MUC5AC ,neoadjuvant therapy ,prognosis ,recurrence ,resectable pancreatic cancer ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Neoadjuvant therapy (NAT) for early-stage pancreatic ductal adenocarcinoma (PDA) has recently gained prominence. We investigated the clinical significance of mucin 5 AC (MUC5AC), which exists in two major glycoforms, a less-glycosylated immature isoform (IM) and a heavily glycosylated mature isoform (MM), as a biomarker in resected PDA. Immunohistochemistry was performed on 100 resected PDAs to evaluate the expression of the IM and MM of MUC5AC using their respective monoclonal antibodies, CLH2 (NBP2-44455) and 45M1 (ab3649). MUC5AC localization (cytoplasmic, apical, and extra-cellular (EC)) was determined, and the H-scores were calculated. Univariate and multivariate (MVA) Cox regression models were used to estimate progression-free survival (PFS) and overall survival (OS). Of 100 resected PDA patients, 43 received NAT, and 57 were treatment-naïve with upfront surgery (UpS). In the study population (n = 100), IM expression (H-scores for objective response vs. no response vs. UpS = 104 vs. 152 vs. 163, p = 0.01) and MM-MUC5AC detection rates (56% vs. 63% vs. 82%, p = 0.02) were significantly different. In the NAT group, MM-MUC5AC-negative patients had significantly better PFS according to the MVA (Hazard Ratio: 0.2, 95% CI: 0.059–0.766, p = 0.01). Similar results were noted in a FOLFIRINOX sub-group (n = 36). We established an association of MUC5AC expression with treatment response and outcomes.
- Published
- 2024
- Full Text
- View/download PDF
24. Safety and Feasibility of Neoadjuvant-Modified FOLFIRINOX in Elderly Patients with Pancreatic Cancer
- Author
-
Yoshitaro Shindo, Tatsuya Ioka, Yukio Tokumitsu, Hiroto Matsui, Masao Nakajima, Yuta Kimura, Yusaku Watanabe, Shinobu Tomochika, Yuki Nakagami, Ryouichi Tsunedomi, Michihisa Iida, Hidenori Takahashi, and Hiroaki Nagano
- Subjects
resectable pancreatic cancer ,borderline resectable pancreatic cancer ,elderly patients ,neoadjuvant chemotherapy ,FOLFIRINOX ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
The optimal treatment strategy for neoadjuvant chemotherapy in elderly patients with pancreatic cancer (PC) remains unclear. Hence, this study was aimed at evaluating the safety and feasibility of neoadjuvant-modified FOLFIRINOX (mFOLFIRINOX) in elderly patients with PC. We retrospectively collected data from 62 patients who received neoadjuvant mFOLFIRINOX between May 2015 and October 2023 and comparatively analyzed the clinicopathological data and outcomes between the non-elderly group (age: 75 years). The non-elderly and elderly groups comprised 39 and 23 patients, respectively. Although elevated levels of aspartate aminotransferase (p = 0.0173) and alanine aminotransferase (p = 0.0378) and nausea (p = 0.0177) were more frequent in the elderly group, the incidence of severe adverse events was similar between the groups. Intergroup differences in resection rate (p = 0.3381), postoperative severe complication rates (p = 0.2450), and postoperative hospital stay (p = 0.3496) were not significant. Furthermore, no significant intergroup differences were found in survival in either the whole or the resection cohorts. The perioperative and postoperative outcomes of elderly patients treated with neoadjuvant mFOLFIRINOX were comparable with those of non-elderly patients. Neoadjuvant mFOLFIRINOX should be considered a feasible option for elderly patients with PC.
- Published
- 2024
- Full Text
- View/download PDF
25. ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing (ARTEMIS)
- Author
-
Eastern Cooperative Oncology Group
- Published
- 2022
26. Impact of Biopsy Attempts, Race, and Access on Time to Initiation of Treatment for Pancreatic Cancer.
- Author
-
Bohan, Riley P., Riner, Andrea N., Herremans, Kelly M., Gao, Hanzhi, Szymkiewicz, Dominique D., Nassour, Ibrahim, Forsmark, Chris E., and Hughes, Steven J.
- Subjects
- *
PANCREATIC cancer , *RACE , *PROPORTIONAL hazards models , *ENDOSCOPIC ultrasonography , *BIOPSY - Abstract
Background: Biopsy of suspected pancreatic cancer (PDAC) in surgical candidates is informative however not always necessary. Biopsies impact treatment options as histological diagnosis are presently required for neo-adjuvant therapy, but not surgical resection. We explored the impact of pursuing tissue diagnosis by endoscopic ultrasound (EUS) biopsy on time to treatment in patients with resectable and borderline resectable PDAC. Methods: A retrospective review of surgical patients with ultimately proven PDAC was performed (2011–2021). Milestone dates (cancer suspected, biopsy(ies), surgical or neo-adjuvant treatment) were collected. Mann–Whitney-Wilcoxon tests, Pearson's chi-squared tests, Fisher's exact tests, linear regressions, and Cox proportional hazard models were used for data analysis. Results: Among 131 resectable and 58 borderline resectable patients, the borderline resectable group underwent more biopsies (1.2 vs 0.7, p < 0.0001), were more likely to undergo biopsy at tertiary care centers (67.2% vs 30.5%, p < 0.0001), and trended toward longer time to treatment (49 vs 44 days, p = 0.070). Significant increases in days to treatment were seen in patients with Black race (29 days, p = 0.0002) and Medicare insurance (22 days, p = 0.038) and no biopsies at a tertiary care center (10 days, p = 0.039). After adjusting for covariates, additional biopsies significantly delayed treatment (1 biopsy: 21 days, p = 0.0001; 2 biopsies: 44 days, p < 0.0001; 3 biopsies: 68 days, p < 0.0001). Conclusions: EUS biopsy significantly impacts time between suspicion and treatment of PDAC. This may be exacerbated by clinical practices increasingly favoring neo-adjuvant therapy that necessitates biopsy-proven disease. Time to treatment may also be impacted by access to tertiary centers and racial disparities. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. The benefits of neoadjuvant therapy for patients with resectable pancreatic cancer: an updated systematic review and meta-analysis.
- Author
-
Yang, Bohan, Chen, Kai, Liu, Weikang, Long, Di, Wang, Yingjin, Liu, Xinxin, Ma, Yongsu, Tian, Xiaodong, and Yang, Yinmo
- Subjects
- *
NEOADJUVANT chemotherapy , *PANCREATIC cancer , *LYMPH nodes , *CANCER invasiveness , *PUBLICATION bias - Abstract
Neoadjuvant therapy (NAT) was effective in improving overall survival (OS) of borderline resectable pancreatic cancer. However, its application in resectable pancreatic cancer remains controversial. This study aimed to determine whether NAT has a greater advantage over conventional upfront surgery (US) in terms of resection rate, R0 resection rate, positive lymph node rate, and OS. We identified articles before October 7, 2022, by searching four electronic databases. The studies included in the meta-analysis all met the inclusion and exclusion criteria. The Newcastle–Ottawa scale was used to evaluate the quality of the articles. OS, DFS, resection rate, R0 resection rate and positive lymph nodes rate were extracted. Odds ratio (OR), hazard ratio (HR) and 95% confidence intervals (CI) were calculated, and sensitivity analysis and publication bias were used to assess the sources of heterogeneity. In total, 24 studies, involving 1384 (35.66%) patients assigned to NAT and 2497 (64.43%) patients assigned to US, were included in the analysis. NAT could effectively prolong OS (HR 0.73, 95% CI 0.65–0.82, P < 0.001) and DFS (HR 0.72, 95% CI 0.62–0.84, P < 0.001). Subgroup analysis results of 6 randomized controlled trials (RCTs) also showed that RPC patients could benefit from NAT in the long term (HR 0.72, 95% CI 0.58–0.90, P = 0.003). NAT decreased resection rate (OR 0.43, 95% CI 0.33–0.55, P < 0.001), but was associated with increased R0 resection rate (OR 2.05, 95% CI 1.47–2.88, P < 0.001) and decreased positive lymph node rate (OR 0.38, 95% CI 0.27–0.52, P < 0.001). Although the application of NAT increases the risk of patients not being able to undergo surgical resection, it can prolong the OS and delay tumor progression in RPC. Therefore, we still expect larger and higher-quality RCTs to confirm the effectiveness of NAT. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study.
- Author
-
Haorui Li, Yu Guo, Xugang Sun, Yang Lu, Shaofei Chang, Xiuchao Wang, Song Gao, Chuntao Gao, and Tiansuo Zhao
- Subjects
PANCREATIC cancer ,GEMCITABINE ,ADJUVANT chemotherapy ,NEOADJUVANT chemotherapy ,PANCREATIC surgery ,CANCER chemotherapy - Abstract
Background: A survival benefit has been seen for both adjuvant nab-paclitaxel plus gemcitabine (AG) and S-1 chemotherapy compared to gemcitabine (GEM) for resectable pancreatic cancer in the APACT (2019) and JASPAC01 trials (2016), respectively. However, supporting evidence regarding the effectiveness of AG or S-1 compared to gemcitabine in real-world clinical practice remains lacking. Methods: Our study included all 246 pancreatic cancer patients who underwent surgical treatment and received postoperative adjuvant chemotherapy with AG, S-1, or GEM except for those meeting exclusion criteria (R2 resection, neoadjuvant therapy, or synchronous malignancy) at Tianjin Medical University Cancer Institute and Hospital from June 2015 to July 2021. The primary outcome was overall survival (OS) and recurrence-free survival (RFS). Results: In total, 246 patients were included, of whom 54(22%) received adjuvant AG, 103(41%) received adjuvant S-1, and 89(37%) received adjuvant GEM. Adjuvant S-1 was associated with a prolonged OS compared to GEM (median OS S-1 vs GEM: 27.0 vs 20.0 months; HR: 0.65, P = .016) and a significantly prolonged RFS compared to GEM (median RFS S-1 vs GEM: 20.0 vs 8.2 months; HR: 0.58, P = .002). After adjusting for known prognostic factors in multivariate Cox regression analysis, this survival benefit persists and is consistent in most subgroups in our subgroup analysis. However, no statistically significant differences in OS or RFS were seen between patients treated with AG and patients treated with GEM. Conclusions: In this retrospective real-world study, adjuvant S-1 chemotherapy was associated with improved survival compared to GEM while no differences in OS or RFS were observed for AG compared to GEM. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. Nomogram for predicting the preoperative lymph node metastasis in resectable pancreatic cancer.
- Author
-
Cheng, Hao, Xu, Jin-Hong, Kang, Xiao-Hong, Liu, Xiao-Mei, Wang, Hai-Feng, Wang, Zhi-Xia, Pan, Hao-Qi, Zhang, Qing-Qin, and Xu, Xue-Lian
- Subjects
- *
LYMPHATIC metastasis , *PANCREATIC cancer , *NOMOGRAPHY (Mathematics) , *RECEIVER operating characteristic curves , *AKAIKE information criterion - Abstract
Background: Lymph node metastasis (LNM) is a critical prognostic factor in resectable pancreatic cancer (PC) patients, determining treatment strategies. This study aimed to develop a clinical model to adequately and accurately predict the risk of LNM in PC patients. Methods: 13,200 resectable PC patients were enrolled from the SEER (Surveillance, Epidemiology, and End Results) database, and randomly divided into a training group and an internal validation group at a ratio of 7:3. An independent group (n = 62) obtained from The First Affiliated Hospital of Xinxiang Medical University was enrolled as the external validation group. The univariate and multivariate logistic regression analyses were used to screen independent risk factors for LNM. The minimum Akaike's information criterion (AIC) was performed to select the optimal model parameters and construct a nomogram for assessing the risk of LNM. The performance of the nomogram was assessed by the receiver operating characteristics (ROC) curve, calibration plot, and decision curve analysis (DCA). In addition, an online web calculator was designed to assess the risk of LNM. Result: A total of six risk predictors (including age at diagnosis, race, primary site, grade, histology, and T-stage) were identified and included in the nomogram. The areas under the curves (AUCs) [95% confidential interval (CI)] were 0.711 (95%CI: 0.700–0.722), 0.700 (95%CI: 0.683–0.717), and 0.845 (95%CI: 0.749–0.942) in the training, internal validation and external validation groups, respectively. The calibration curves showed satisfied consistency between nomogram-predicted LNM and actual observed LNM. The concordance indexes (C-indexes) in the training, internal, and external validation sets were 0.689, 0.686, and 0.752, respectively. The DCA curves of the nomogram demonstrated good clinical utility. Conclusion: We constructed a nomogram model for predicting LNM in pancreatic cancer patients, which may help oncologists and surgeons to choose more individualized clinical treatment strategies and make better clinical decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. The CA125 level postoperative change rule and its prognostic significance in patients with resectable pancreatic cancer
- Author
-
Xin Luo, Xianchao Lin, Ronggui Lin, Yuanyuan Yang, Congfei Wang, Haizong Fang, Heguang Huang, and Fengchun Lu
- Subjects
Resectable pancreatic cancer ,CA125 ,Early recurrence ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background The relationship between postoperative CA125 level changes and early recurrence after curative resection of resectable PDAC is still unclear. Methods The electronic medical records and follow-up data of patients with resectable pancreatic cancer were evaluated. Dynamic CA125 detection was used to identify the rules for postoperative CA125 level change and its prognostic value in patients with resectable pancreatic cancer. Results The study included a total of 118 patients with resectable pancreatic cancer who underwent curative resection. Early postoperative CA125 levels were significantly higher than those before surgery (P 0.05). There was no correlation between early postoperative CA125 levels and early recurrence (P > 0.05). CA125 levels three months after surgery were associated with an increased risk of early recurrence (P = 0.038, 95% CI (1.001–1.025)). The cutoff CA125 level at 3 months after surgery for predicting early recurrence was 22.035. Patients with CA125 levels 22.035 at 3 months postoperatively (p 3 months postoperatively, rather than early postoperative elevation, were associated with a poor prognosis.
- Published
- 2023
- Full Text
- View/download PDF
31. Focus on Therapeutic Options for Surgically Resectable Pancreatic Adenocarcinoma Based on Novel Biomarkers
- Author
-
Alessandro Olivari, Virginia Agnetti, and Ingrid Garajová
- Subjects
neoadjuvant therapy ,resectable pancreatic cancer ,novel biomarkers ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Pancreatic ductal adenocarcinoma remains associated with a poor prognosis, even when diagnosed at an early stage. Consequently, it is imperative to carefully consider the available therapeutic options and tailor them based on clinically relevant biomarkers. In our comprehensive review, we specifically concentrated on the identification of novel predictive and prognostic markers that have the potential to be integrated into multiparametric scoring systems. These scoring systems aim to accurately predict the efficacy of neoadjuvant chemotherapy in surgically resectable pancreatic cancer cases. By identifying robust predictive markers, we can enhance our ability to select patients who are most likely to benefit from neoadjuvant chemotherapy. Furthermore, the identification of prognostic markers can provide valuable insights into the overall disease trajectory and inform treatment decisions. The development of multiparametric scoring systems that incorporate these markers holds great promise for optimizing the selection of patients for neoadjuvant chemotherapy, leading to improved outcomes in resectable pancreatic neoplasia. Continued research efforts are needed to validate and refine these markers and scoring systems, ultimately advancing the field of personalized medicine in pancreatic adenocarcinoma management.
- Published
- 2023
- Full Text
- View/download PDF
32. Neo-Adjuvant Treatment in Primary Resectable Pancreatic Cancer: A Systematic Review and PRISMA-Compliant Updated Metanalysis of Oncological Outcomes.
- Author
-
Roesel, Raffaello, Deantonio, Letizia, Bernardi, Lorenzo, Garo, Maria Luisa, Majno-Hurst, Pietro, Vannelli, Alberto, Cefalì, Marco, Palmarocchi, Maria Celeste, Valli, Maria Carla, Pesola, Guido, Cristaudi, Alessandra, and De Dosso, Sara
- Subjects
- *
PANCREATIC tumors , *ONLINE information services , *MEDICAL databases , *META-analysis , *CONFIDENCE intervals , *MEDICAL information storage & retrieval systems , *SYSTEMATIC reviews , *METASTASIS , *TREATMENT effectiveness , *COMPARATIVE studies , *ADJUVANT treatment of cancer , *CHEMORADIOTHERAPY , *SURVIVAL analysis (Biometry) , *DESCRIPTIVE statistics , *COMBINED modality therapy , *PROGRESSION-free survival , *ODDS ratio , *MEDLINE , *CANCER patient medical care , *OVERALL survival , *EVALUATION - Abstract
Simple Summary: Pancreatic adenocarcinoma is the fourth leading cause of cancer-related death in industrialized countries. In locally advanced and borderline resectable pancreatic cancer, neoadjuvant therapy (NAT) has been shown to be effective in eliminating potentially circulating tumor cells and distant micrometastases, shrinking local tumors, and identifying high-grade malignancies that do not benefit from surgery. However, in patients with resectable pancreatic adenocarcinoma, who represent 20% of new diagnoses and for whom US followed by adjuvant chemotherapy is the standard of care, NAT is controversial because it carries several potential drawbacks that may prevent surgery and increase the risk of clinical deterioration. Randomized clinical trials, retrospective studies, and a few systematic reviews and meta-analyses reported controversial results, and although the safety and feasibility of such an approach are supported, a wider implementation is still a matter of debate. Considering the different methodological approaches (RCTs vs. retrospective studies), the difficulty in providing high-quality evidence due to small patient numbers, and the emergence of new evidence, an update of the current evidence seems essential to help clinicians and researchers understand the role of NAT and offer a new potentially beneficial treatment approach. Thus, the aim of this systematic review and meta-analysis is to evaluate the role of NAT in prolonging overall survival and disease-free survival and improving R0 and N0 rates compared with upfront resection in patients with resectable pancreatic cancer. Background: Despite advances in treatment, the prognosis of resectable pancreatic adenocarcinoma remains poor. Neoadjuvant therapy (NAT) has gained great interest in hopes of improving survival. However, the results of available studies based on different treatment approaches, such as chemotherapy and chemoradiotherapy, showed contrasting results. The aim of this systematic review and meta-analysis is to clarify the benefit of NAT compared to upfront surgery (US) in primarily resectable pancreatic adenocarcinoma. Methods: A PRISMA literature review identified 139 studies, of which 15 were finally included in the systematic review and meta-analysis. All data from eligible articles was summarized in a systematic summary and then used for the meta-analysis. Specifically, we used HR for OS and DFS and risk estimates (odds ratios) for the R0 resection rate and the N+ rate. The risk of bias was correctly assessed according to the nature of the studies included. Results: From the pooled HRs, OS for NAT patients was better, with an HR for death of 0.80 (95% CI: 0.72–0.90) at a significance level of less than 1%. In the sub-group analysis, no difference was found between patients treated with chemoradiotherapy or chemotherapy exclusively. The meta-analysis of seven studies that reported DFS for NAT resulted in a pooled HR for progression of 0.66 (95% CI: 0.56–0.79) with a significance level of less than 1%. A significantly lower risk of positive lymph nodes (OR: 0.45; 95% CI: 0.32–0.63) and an improved R0 resection rate (OR: 1.70; 95% CI: 1.23–2.36) were also found in patients treated with NAT, despite high heterogeneity. Conclusions: NAT is associated with improved survival for patients with resectable pancreatic adenocarcinoma; however, the optimal treatment strategy has yet to be defined, and further studies are required. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. The CA125 level postoperative change rule and its prognostic significance in patients with resectable pancreatic cancer.
- Author
-
Luo, Xin, Lin, Xianchao, Lin, Ronggui, Yang, Yuanyuan, Wang, Congfei, Fang, Haizong, Huang, Heguang, and Lu, Fengchun
- Subjects
- *
PANCREATIC cancer , *ELECTRONIC health records , *POSTOPERATIVE period , *PROGNOSIS - Abstract
Background: The relationship between postoperative CA125 level changes and early recurrence after curative resection of resectable PDAC is still unclear. Methods: The electronic medical records and follow-up data of patients with resectable pancreatic cancer were evaluated. Dynamic CA125 detection was used to identify the rules for postoperative CA125 level change and its prognostic value in patients with resectable pancreatic cancer. Results: The study included a total of 118 patients with resectable pancreatic cancer who underwent curative resection. Early postoperative CA125 levels were significantly higher than those before surgery (P < 0.05). It decreased gradually in the group without early recurrence (P < 0.05) but not in the early recurrence group (P>0.05). There was no correlation between early postoperative CA125 levels and early recurrence (P > 0.05). CA125 levels three months after surgery were associated with an increased risk of early recurrence (P = 0.038, 95% CI (1.001–1.025)). The cutoff CA125 level at 3 months after surgery for predicting early recurrence was 22.035. Patients with CA125 levels < 22.035 three months postoperatively had similar DFS and OS, regardless of whether the value was exceeded in the early postoperative period, but these values were significantly better than those of patients with CA125 levels > 22.035 at 3 months postoperatively (p < 0.05). Conclusions: Patients with different prognoses have different patterns of CA125 level changes. Elevations in CA125 levels > 3 months postoperatively, rather than early postoperative elevation, were associated with a poor prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Focus on Therapeutic Options for Surgically Resectable Pancreatic Adenocarcinoma Based on Novel Biomarkers.
- Author
-
Olivari, Alessandro, Agnetti, Virginia, and Garajová, Ingrid
- Subjects
- *
PATIENT selection , *PROGNOSIS , *NEOADJUVANT chemotherapy , *ADENOCARCINOMA , *PANCREATIC duct , *PANCREATIC intraepithelial neoplasia - Abstract
Pancreatic ductal adenocarcinoma remains associated with a poor prognosis, even when diagnosed at an early stage. Consequently, it is imperative to carefully consider the available therapeutic options and tailor them based on clinically relevant biomarkers. In our comprehensive review, we specifically concentrated on the identification of novel predictive and prognostic markers that have the potential to be integrated into multiparametric scoring systems. These scoring systems aim to accurately predict the efficacy of neoadjuvant chemotherapy in surgically resectable pancreatic cancer cases. By identifying robust predictive markers, we can enhance our ability to select patients who are most likely to benefit from neoadjuvant chemotherapy. Furthermore, the identification of prognostic markers can provide valuable insights into the overall disease trajectory and inform treatment decisions. The development of multiparametric scoring systems that incorporate these markers holds great promise for optimizing the selection of patients for neoadjuvant chemotherapy, leading to improved outcomes in resectable pancreatic neoplasia. Continued research efforts are needed to validate and refine these markers and scoring systems, ultimately advancing the field of personalized medicine in pancreatic adenocarcinoma management. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
35. Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
- Author
-
Hangzhou Neoantigen Therapeutics Co., Ltd. and Liu Yang, MD
- Published
- 2021
36. Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma (PIOPPO)
- Author
-
Foundation IRCCS San Matteo Hospital and Francesca Valvo, Principal investigator
- Published
- 2021
37. Diagnostic Bioliquid Markers for Pancreatic Cancer: What We Have vs. What We Need.
- Author
-
Liou, Geou-Yarh and Byrd, Crystal J.
- Subjects
- *
PANCREATIC tumors , *ADENOCARCINOMA , *DELAYED diagnosis , *EARLY detection of cancer , *METASTASIS , *DUCTAL carcinoma , *SURVIVAL rate , *TUMOR markers , *CELL lines , *TUMOR antigens , *EARLY diagnosis ,BODY fluid examination - Abstract
Simple Summary: Among all types of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC) is the most common type and has an extremely low survival rate. Early detection at an early stage, when surgical removal is still available, is crucial to minimize the death toll of the individuals who are dying from PDAC. In this review, we have summarized the liquid biomarkers that are currently being used to diagnose PDAC in the clinic, clinical trials, and under development for potential use in the future. This review also provides insight into future liquid biomarkers that may be used in routine examinations for the early diagnosis of PDAC development and its precursors, hoping to significantly decrease PDAC death numbers. Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, currently has a dismal five-year survival rate of approximately 10% due to late diagnosis and a lack of efficient treatment options such as surgery. Furthermore, the majority of PDAC patients have surgically unresectable cancer, meaning cancer cells have either reached the surrounding blood vessels or metastasized to other organs distant from the pancreas area, resulting in low survival rates as compared to other types of cancers. In contrast, the five-year survival rate of surgically resectable PDAC patients is currently 44%. The late diagnosis of PDAC is a result of little or no symptoms in its early stage of development and a lack of specific biomarkers that may be utilized in routine examinations in the clinic. Although healthcare professionals understand the importance of early detection of PDAC, the research on the subject has lagged and no significant changes in the death toll of PDAC patients has been observed. This review is focused on understanding potential biomarkers that may increase the early diagnosis of PDAC patients at its surgically resectable stage. Here, we summarize the currently available biomarkers used in the clinic as well as those being developed with the hope of providing insight into the future of liquid biomarkers to be used in routine examinations for the early diagnosis of PDAC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
38. Circulating CD8+CD122+ T cells as a prognostic indicator of pancreatic cancer
- Author
-
Katsuhito Teramatsu, Takamasa Oono, Koki Oyama, Nao Fujimori, Masatoshi Murakami, Sho Yasumori, Akihisa Ohno, Kazuhide Matsumoto, Ayumu Takeno, Kohei Nakata, Masafumi Nakamura, and Yoshihiro Ogawa
- Subjects
Metastatic pancreatic cancer ,Resectable pancreatic cancer ,Benign pancreatic cysts ,CD4+ T cells ,CD8+CD122+ T cells ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Purpose The distribution of tissue infiltrating lymphocytes has been shown to affect the prognosis of patients with pancreatic cancer in some previous studies. However, the role of peripheral lymphocytes in pancreatic cancer remains debated. The purpose of this study was to analyze the peripheral subtypes of T lymphocytes, and establish their association with the prognosis of patients with pancreatic cancer. Methods Blood and tissue samples were collected from patients with metastatic pancreatic cancer (n = 54), resectable pancreatic cancer (n = 12), and benign pancreatic cysts (n = 52) between April 2019 and January 2022 and analyzed. Results Patients with metastatic pancreatic cancer had a larger proportion of both tumor-suppressive and tumor-promoting cells than those with benign pancreatic cysts. In addition, the proportion of peripheral CD4+ T cells positively correlated with the survival of patients with metastatic pancreatic cancer, and the proportion of peripheral CD8+CD122+ T cells was associated with early mortality (
- Published
- 2022
- Full Text
- View/download PDF
39. Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer
- Author
-
Varian Medical Systems
- Published
- 2021
40. Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study
- Published
- 2021
41. Fibrinogen-to-prealbumin ratio: A new prognostic marker of resectable pancreatic cancer.
- Author
-
Chengqing Li, Zhiyao Fan, Wenyi Guo, Feng Liang, Xincheng Mao, Jiahao Wu, Haodong Wang, Jianwei Xu, Dong Wu, Han Liu, Lei Wang, and Feng Li
- Subjects
PANCREATIC cancer ,PROGNOSIS ,RECEIVER operating characteristic curves ,CARCINOEMBRYONIC antigen ,PANCREATIC intraepithelial neoplasia ,DECISION making - Abstract
Background: The fibrinogen-to-prealbumin ratio (FPR), a novel immunenutritional biomarker, has been reported to be associated with prognosis in several types of cancer, but the role of FPR in the prognosis of resectable pancreatic cancer has not been elucidated. Methods: A total of 263 patients with resectable pancreatic cancer were enrolled in this study and were randomly divided into a training cohort (n = 146) and a validation cohort (n = 117). Receiver operating characteristic curve (ROC) was used to calculate the cut-off values of immune-nutritional markers. The least absolute shrinkage and selection operator (LASSO) regression and multivariate Cox regression were performed in the training cohort to identify the independent risk factors, based on which the nomogram was established. The performance of the nomogram was evaluated and validation by the training and validation cohort, respectively. Results: The optimal cutoff value for FPR was 0.29. Multivariate analysis revealed that FPR, controlling nutritional status (CONUT), carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), and tumor node metastasis (TNM) stage were independent predictors of overall survival (OS). The nomogram was established by involving the five factors above. The C-index of the training cohort and validation cohort were 0.703 (95% CI: 0.0.646-0.761) and 0.728 (95% CI: 0.671-0.784). Decision curve analysis and time-dependent AUC showed that the nomogram had better predictive and discriminative ability than the conventional TNM stage. Conclusion: FPR is a feasible biomarker for predicting prognosis in patients with resectable pancreatic cancer. The nomogram based on FPR is a useful tool for clinicians in making individualized treatment strategies and survival predictions. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
42. Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and network meta-analysis.
- Author
-
Li, Xujia, Huang, Jinsheng, Jiang, Chang, Chen, Ping, Quan, Qi, Jiang, Qi, Li, Shengping, and Guo, Guifang
- Subjects
- *
PANCREATIC tumors , *META-analysis , *CONFIDENCE intervals , *SYSTEMATIC reviews , *CANCER chemotherapy , *TREATMENT effectiveness , *CHEMORADIOTHERAPY , *COMPARATIVE studies , *RESEARCH funding , *DESCRIPTIVE statistics , *COMBINED modality therapy , *PATIENT safety , *OVERALL survival - Abstract
Background: To date, the optimal recommended specific neoadjuvant regimens for resectable or borderline resectable pancreatic cancer (RPC or BRPC) remain an unanswered issue. Methods: We systematically searched the electronic databases to identify randomized controlled trials (RCTs) comparing different neoadjuvant therapy strategies for RPC or BRPC. The primary outcome was overall survival (OS). Comprehensive analyses and evaluations were performed using the single-arm, paired, and network meta-analyses. Results: Twelve RCTs involving 1279 patients with RPC or BRPC were enrolled. The paired meta-analysis showed that neoadjuvant therapy improved OS for both RPC (hazard ratio (HR) 0.69, 95% c.i. 0.54 to 0.87) and BRPC (HR 0.60, 0.42 to 0.86) compared with upfront surgery (UP-S). Neoadjuvant chemotherapy (NAC) also improved OS for both RPC (HR 0.63, 0.47 to 0.85) and BRPC (HR 0.44, 0.27 to 0.71), while neoadjuvant chemoradiotherapy (NACR) improved OS only for BRPC (HR 0.68, 0.52 to 0.89) and not for RPC (HR 0.79, 0.54 to 1.16). Network meta-analysis found that NAC was superior to NACR in OS for RPC/BRPC (HR 0.58, 0.37 to 0.90). Neoadjuvant chemotherapy based on modified fluorouracil/folinic acid/irinotecan/oxaliplatin (NAC-mFFX) and neoadjuvant chemotherapy based on abraxane/gemcitabine (NAC-AG) ranked first and second in OS for RPC/BRPC. Conclusions: Both RPC and BRPC could obtain OS benefits from neoadjuvant therapy compared with UP-S, and NAC improved OS both in RPC and BRPC while NACR only improved OS in BRPC. Furthermore, NAC was superior to NACR, and NAC-mFFX and NAC-AG might be recommended sequentially as the best neoadjuvant therapy strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
43. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group.
- Author
-
Seufferlein, T., Uhl, W., Kornmann, M., Algül, H., Friess, H., König, A., Ghadimi, M., Gallmeier, E., Bartsch, D.K., Lutz, M.P., Metzger, R., Wille, K., Gerdes, B., Schimanski, C.C., Graupe, F., Kunzmann, V., Klein, I., Geissler, M., Staib, L., and Waldschmidt, D.
- Subjects
- *
PANCREATIC cancer , *NEOADJUVANT chemotherapy , *GEMCITABINE , *ADJUVANT chemotherapy , *PANCREATIC duct - Abstract
Data on perioperative chemotherapy in resectable pancreatic ductal adenocarcinoma (rPDAC) are limited. NEONAX examined perioperative or adjuvant chemotherapy with gemcitabine plus nab-paclitaxel in rPDAC (National Comprehensive Cancer Network criteria). NEONAX is a prospective, randomized phase II trial with two independent experimental arms. One hundred twenty-seven rPDAC patients in 22 German centers were randomized 1 : 1 to perioperative (two pre-operative and four post-operative cycles, arm A) or adjuvant (six cycles, arm B) gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2) on days 1, 8 and 15 of a 28-day cycle. The primary endpoint was disease-free survival (DFS) at 18 months in the modified intention-to-treat (ITT) population [R0/R1-resected patients who started neoadjuvant chemotherapy (CTX) (A) or adjuvant CTX (B)]. The pre-defined DFS rate of 55% at 18 months was not reached in both arms [A: 33.3% (95% confidence interval [CI] 18.5% to 48.1%), B: 41.4% (95% CI 20.7% to 62.0%)]. Ninety percent of patients in arm A completed neoadjuvant treatment, and 42% of patients in arm B started adjuvant chemotherapy. R0 resection rate was 88% (arm A) and 67% (arm B), respectively. Median overall survival (mOS) (ITT population) as a secondary endpoint was 25.5 months (95% CI 19.7-29.7 months) in arm A and 16.7 months (95% CI 11.6-22.2 months) in the upfront surgery arm. This difference corresponds to a median DFS (mDFS) (ITT) of 11.5 months (95% CI 8.8-14.5 months) in arm A and 5.9 months (95% CI 3.6-11.5 months) in arm B. Treatment was safe and well tolerable in both arms. The primary endpoint, DFS rate of 55% at 18 months (mITT population), was not reached in either arm of the trial and numerically favored the upfront surgery arm B. mOS (ITT population), a secondary endpoint, numerically favored the neoadjuvant arm A [25.5 months (95% CI 19.7-29.7months); arm B 16.7 months (95% CI 11.6-22.2 months)]. There was a difference in chemotherapy exposure with 90% of patients in arm A completing pre-operative chemotherapy and 58% of patients starting adjuvant chemotherapy in arm B. Neoadjuvant/perioperative treatment is a novel option for patients with resectable PDAC. However, the optimal treatment regimen has yet to be defined. The trial is registered with ClinicalTrials.gov (NCT02047513) and the European Clinical Trials Database (EudraCT 2013–005559-34). Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer: • Did not meet its primary endpoint in either arm of the study (DFS rate at 18 months of 55% in the mITT population). • Showed that pre-operative chemotherapy can be completed by the majority of patients (90%). • Showed an mOS as a secondary endpoint of 25.5 months in arm A (perioperative) and 16.7 months in arm B (upfront surgery). • Gemcitabine and nab-paclitaxel were safe and well tolerated both in the perioperative as well as the adjuvant setting. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
44. EUS vs. MDCT in Pancreatic Malignancy (EUSPACT)
- Author
-
University of Medicine and Pharmacy Craiova, Iuliu Hatieganu University of Medicine and Pharmacy, Institutul Clinic Fundeni, and Mihai Rimbas, MD, PhD, Assistant Professor
- Published
- 2020
45. Circulating CD8+CD122+ T cells as a prognostic indicator of pancreatic cancer.
- Author
-
Teramatsu, Katsuhito, Oono, Takamasa, Oyama, Koki, Fujimori, Nao, Murakami, Masatoshi, Yasumori, Sho, Ohno, Akihisa, Matsumoto, Kazuhide, Takeno, Ayumu, Nakata, Kohei, Nakamura, Masafumi, and Ogawa, Yoshihiro
- Subjects
- *
PANCREATIC tumors , *PANCREATIC cysts , *CELL physiology , *PROGNOSIS , *LYMPHOCYTES , *T cells - Abstract
Purpose: The distribution of tissue infiltrating lymphocytes has been shown to affect the prognosis of patients with pancreatic cancer in some previous studies. However, the role of peripheral lymphocytes in pancreatic cancer remains debated. The purpose of this study was to analyze the peripheral subtypes of T lymphocytes, and establish their association with the prognosis of patients with pancreatic cancer.Methods: Blood and tissue samples were collected from patients with metastatic pancreatic cancer (n = 54), resectable pancreatic cancer (n = 12), and benign pancreatic cysts (n = 52) between April 2019 and January 2022 and analyzed.Results: Patients with metastatic pancreatic cancer had a larger proportion of both tumor-suppressive and tumor-promoting cells than those with benign pancreatic cysts. In addition, the proportion of peripheral CD4+ T cells positively correlated with the survival of patients with metastatic pancreatic cancer, and the proportion of peripheral CD8+CD122+ T cells was associated with early mortality (< 90 days). After chemotherapy, CD8+CD122+ T cells decreased in patients who had a partial response or stable disease. Moreover, by analyzing resected specimens, we first proved that the existence of CD8+CD122+ T cells in a tumor microenvironment (TME) depends on their proportion in peripheral blood.Conclusion: Circulating CD8+CD122+ T cells can be a prognostic indicator in patients with pancreatic cancer. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
46. Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer
- Author
-
Aoki, Shuichi, Unno, Michiaki, Isayama, Hiroyuki, editor, Nakai, Yousuke, editor, and Sasaki, Takashi, editor
- Published
- 2021
- Full Text
- View/download PDF
47. Neo-Adjuvant Treatment in Primary Resectable Pancreatic Cancer: A Systematic Review and PRISMA-Compliant Updated Metanalysis of Oncological Outcomes
- Author
-
Raffaello Roesel, Letizia Deantonio, Lorenzo Bernardi, Maria Luisa Garo, Pietro Majno-Hurst, Alberto Vannelli, Marco Cefalì, Maria Celeste Palmarocchi, Maria Carla Valli, Guido Pesola, Alessandra Cristaudi, and Sara De Dosso
- Subjects
resectable pancreatic cancer ,pancreatic adenocarcinoma ,neoadjuvant chemotherapy ,neoadjuvant chemoradiotherapy ,neo-adjuvant treatment ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background: Despite advances in treatment, the prognosis of resectable pancreatic adenocarcinoma remains poor. Neoadjuvant therapy (NAT) has gained great interest in hopes of improving survival. However, the results of available studies based on different treatment approaches, such as chemotherapy and chemoradiotherapy, showed contrasting results. The aim of this systematic review and meta-analysis is to clarify the benefit of NAT compared to upfront surgery (US) in primarily resectable pancreatic adenocarcinoma. Methods: A PRISMA literature review identified 139 studies, of which 15 were finally included in the systematic review and meta-analysis. All data from eligible articles was summarized in a systematic summary and then used for the meta-analysis. Specifically, we used HR for OS and DFS and risk estimates (odds ratios) for the R0 resection rate and the N+ rate. The risk of bias was correctly assessed according to the nature of the studies included. Results: From the pooled HRs, OS for NAT patients was better, with an HR for death of 0.80 (95% CI: 0.72–0.90) at a significance level of less than 1%. In the sub-group analysis, no difference was found between patients treated with chemoradiotherapy or chemotherapy exclusively. The meta-analysis of seven studies that reported DFS for NAT resulted in a pooled HR for progression of 0.66 (95% CI: 0.56–0.79) with a significance level of less than 1%. A significantly lower risk of positive lymph nodes (OR: 0.45; 95% CI: 0.32–0.63) and an improved R0 resection rate (OR: 1.70; 95% CI: 1.23–2.36) were also found in patients treated with NAT, despite high heterogeneity. Conclusions: NAT is associated with improved survival for patients with resectable pancreatic adenocarcinoma; however, the optimal treatment strategy has yet to be defined, and further studies are required.
- Published
- 2023
- Full Text
- View/download PDF
48. Neoadjuvant treatment of pancreatic ductal adenocarcinoma.
- Author
-
Kosma, Katharina, Thalhammer, Sabine, and Gruenberger, Thomas
- Abstract
Summary: Neoadjuvant therapy in resectable and borderline resectable pancreatic cancer is the subject of several ongoing randomized controlled trials (RCTs). Retrospective studies and completed RCTs favor the use of neoadjuvant therapy in pancreatic cancer. Yet, the optimal chemotherapy regimen has not been defined. The objective of this report is to provide a review of currently available study data of neoadjuvant therapy in pancreatic cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
49. Borderline Pancreas Study: FOLFIRINOX +SBRT (GCC 1324)
- Author
-
Department of Radiation Oncology, Principal Investigator
- Published
- 2019
50. Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients
- Author
-
Celgene
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.